Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)

CAPS Rating: 3 out of 5

A clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases.


Player Avatar JorgeAura (< 20) Submitted: 12/6/2012 7:36:25 PM : Underperform Start Price: $8.63 ARNA Score: -2.25

This company have a good future. But, at this moment is overvalued.

Featured Broker Partners